Two long-acting ß 2 -adrenergic agonists (LABAs), salmeterol and formoterol, have been demonstrated to be safe and effective agents in children, both in terms of bronchodilation and prevention of exercise-induced bronchospasm. Their onsets of action differ, with formoterol having an onset similar to albuterol (3 minutes), while salmeterol has a slower onset of action (10–20 minutes). Following a single-dose administration, both agents demonstrate durations of action up to 12 hours. Following regular twice-daily administration, bronchodilation remains effective; however, a level of tolerance (or tachyphylaxis) (more…)

Despite optimum drug delivery and good compliance with inhaled corticosteroids, many patients experience symptoms and exacerbations. Dose–response studies using inhaled corticosteroids have generally been unable to demonstrate any significant difference between individual doses of inhaled corticosteroids. For example, a metaanalysis evaluated eight studies (2324 asthmatics) where the effects of at least two doses of inhaled fluticasone were measured. (more…)

The genetic basis of asthma heritability has been extensively studied and the studies are yielding some understanding. There is, as yet, no set genetic pattern that predicts presence of asthma or defines it severity. There are usually reasons or risk of asthma factors that makes someone susceptible to asthma and respiratory allergy problems. Asthma doesn’t just happen randomly to anyone without asthma gene factors risk factors.

Let’s consider some asthma risk factors and see how they increase the chance that a individual will have the asthma signs or symptoms of cough, wheezing, as well as shortness of breathing associated with the disease. After determining your personal risk factors for asthma, decide on the ones you can control as well as try to make some lifestyle changes. Avoidance of the risk factors you can control is important in preventing asthma symptoms. While you cannot change your own gender to family history, you can avoid smoking with asthma, breathing polluted air, and obesity. Take control of your asthma by controlling the asthma risk factors. By understanding all of the risk factors, you are able to prevent to control your asthma.

Genetic factors cannot explain the rise in asthma prevalence, morbidity, or mortality. However, a small change in the prevalence of relevant environmental exposures could explain a significant rise in disease prevalence among genetically susceptible individuals. Gene-environment interaction, defined as the co-participation of genetic and environmental factors, is particularly relevant to the etiology of asthma morbidity, especially in individuals who experience a disproportionate burden of environmental exposures. Relevant exposures include smoking, stress, nutritional factors, infections, allergens, and occupational asthma exposures. In addition, racial/ethnic variability in the distribution of genetic polymorphisms can potentially modify the response to pharmacotherapeutic agents, such as the ß 2 -adrenergic receptor. A genetic polymorphism in the ß 2 -adrenergic receptor gene has been associated with asthma severity, as well as with the susceptibility to develop asthma among individuals who smoked.

Childhood asthma happens more frequently in boys than in girls. It is still not known precisely why this occurs even though some experts find a young male’s airway size is small compared to the female’s airway, that may contribute to increased risk of wheezing after a cold or perhaps other viral infection. Around age 20, the ratio of asthma between people is the same. At age 40, more females than men have adult asthma.

The inherited genetic makeup predisposes you to having asthma. In fact, it’s thought that three-fifths of all asthma cases are hereditary. Based on CDC report, if a person has a parent with asthma, there is 3 to 6 times more probably to develop asthma than someone who does definitely not have a parent with asthma.

Maintenance of asthma control by once-daily inhaled ciclesonide nasal spray in adults with persistent asthma. Ciclesonide is an inhaled corticosteroid that is converted to an active metabolite, desisobutyryl ciclesonide, in the lungs, thereby minimizing effects on endogenous cortisol inflammation. The goal of finding newer, safer corticosteroids for the management of asthma has led to the development of this inhaled corticosteroid.

This 12-week, double-blind, randomized, parallel-group, placebo-controlled study evaluated the efficacy and safety of ciclesonide in adults with persistent asthma. Efficacy was monitored with asthma symptom scores, rescue medication use, morning and evening peak expiratory flow rate (PEF) measurements, spirometry, and the probability of study completion without experiencing lack of efficacy. It was concluded that ciclesonide (160 or 640 µg) once daily in the morning maintains asthma control effectively, does not affect cortisol levels, and has an adverse event profile comparable with that of placebo in adults with primarily mild to moderate asthma.

It has been reported previously that, compared with fluticasone, ciclesonide possesses equivalent anti-inflammatory efficacy, through pulmonary activation, with a significantly improved safety profile. Since it has low bioavailability because it is metabolized by the lung, it is believed to cause minimal systemic adverse effects. It was found that the morning peak expiratory flow rate (PEF) and FEV 1 values from patient diaries decreased significantly in patients switched from their usual inhaled corticosteroids therapy to placebo but remained stable in patients switched to either dose of ciclesonide (160 or 640 µg). Furthermore, in patients switched to placebo there were significant increases in daily asthma symptoms and the use of rescue medication, with no significant changes from baseline in patients switched to either dose of ciclesonide. Mean changes from baseline in serum and urinary cortisol levels were not statistically significant in any of the treatment groups. Adverse effects were mild, with no reported cases of oral candidiasis.

In conclusion, once-daily inhaled ciclesonide nasal spray (160 or 640 µg) was superior to placebo in the maintenance of asthma control in adult patients previously treated with moderate doses of inhaled corticosteroids, without any significant adverse effects.

Tumour necrosis factor alpha (TNF-a) is a major therapeutic target in a range of chronic inflammatory disorders involving neutrophils and its excess production is characterized by a Th1-type immune response. Asthma is regarded as a Th2-type disorder when associated with atopy, (more…)

Acetylcholine is a neurotransmitter of the nerve vagus, the functional effects mediated by binding to muscarinic receptors. Results from stimulation of acetylcholine on the contraction of myoepithelial cells around bronchial submucosal glands and thus to acetylcholine airway obstruction may bronchial provocation tests in the measurement of bronchial hyperresponsiveness may be used with others. (more…)

Interleukin-5 is the key cytokine in eosinophil differentiation and growth in the bone marrow and stimulates the release of eosinophils into the peripheral circulation. Thus, it is thought that IL-5 may be involved in the pathogenesis of hypereosinophilic syndromes (HES), a diverse group of poorly treated disorders characterized by sustained peripheral blood and/or tissue eosinophilia. Mepolizumab is a humanized monoclonal antibody to IL-5, and its safety and efficacy were assessed in this open-labelled trial. (more…)

There is increasing evidence relating body mass index to the prevalence of asthma and incidence of asthma in children and adults, males, and more consistently, in adolescent females. It is unlikely that the association is attributable to reverse causation, i.e. that asthma and obesity because of exercise-induced asthma symptoms. Rather, weight gain can antedate the development of asthma. Weight reduction among asthmatic patients can also result in improvements of lung function. (more…)

Antihistamines have been shown to be effective in seasonal allergic rhinitis and chronic idiopathic urticaria. They improve quality of life scores, acute inflammatory response markers in atopic dermatitis asthma and symptom scores. Newer histamine H1-receptor antagonists may also have an antiplatelet-activating factor effect and are equally effective in seasonal allergic rhinitis. The antileukotrienes were developed in the 1980s. The first compounds of this novel class of anti-asthma drugs were registered in the second half of the 1990s. The mechanism of action of the cysteinyl leukotriene receptor antagonists (LTRAs) is based on counteracting the effects of cysteinyl leukotrienes at their receptor site (CysLT1 receptor) within the airways. (more…)

By definition, allergy is a condition where a person has hypersensitivity to an environmental, drug, or food antigen (allergen) caused by an altered or unusual immune system reaction to the antigen.

Allergenic foods can impact the lungs when an allergic reaction individual inhales food particles that may have been released when the food was cooked or that were dispersed in aerosol form. Allergy to the allergens in cooked food has been reported by highly allergic patients who were exposed to their allergenic foods (say, fish, shellfish, or eggs) in an enclosed area (for example, a restaurant dining room) or during meal preparation. Most cases of asthma triggered by aerosolized food allergens involve adults engaged in specific occupations that regularly expose them to the allergens. In contrast, most cases of asthma in children are triggered when the allergen is eaten, not inhaled.

Many experts believe that if a baby can be protected from becoming sensitized to the most highly allergenic foods when their healthy immune system and the digestive tract are in the most vulnerable stage for allergy to develop, the incidence of lifelong food allergy and potentially life-threatening anaphylactic reactions to foods will be reduced and hopefully entirely prevented. When a baby has been identified to be at risk for developing allergy, measures to reduce allergic sensitization might be implemented at birth and the problems associated with future food allergy may be significantly reduced. However, as we shall see in later discussions, experts disagree on the best way to avoid this early allergic sensitization.

The reaction of asthmatics to these chemical compounds is not an allergy, but is more correctly described as allergy intolerance because the initial response is not a triggering of the immune system. The process involves an increase in the level of the inflammatory mediators that are responsible for the bronchospasm of asthma. These mediators include histamine and leukotrienes. They are released during the reaction to an allergen, and cause the muscular contractions that result in the difficulty in breathing and wheezing that are typical of asthma. By inhibiting (or turning off) other types of mediators, the chemicals in the food additives cause an increase in the level of antihistamine and leukotrienes. This results in increased bronchospasm, and a definite worsening of the asthma symptoms.

Oral allergy syndrome is an allergic reaction to food that is confined to the oral cavity (i.e., to the lips, and around the lips, roof of the mouth, tongue, hard and soft palate, and uvula) and adjacent structures. It differs from other food allergy in that its symptoms do not appear in any other location in the body, and always accompany respiratory allergy to inhaled allergens of plants, particularly plant pollens. Of course, symptoms in the mouth, throat, and upper respiratory tract can be part of a generalized reaction to foods, but in this case they are more accurately described as oral allergy symptoms. The term oral allergy syndrome applies specifically to pollen allergy (pollinosis) accompanied by reactions to certain raw foods when they are in direct contact with oral tissues. Individuals with Oral allergy syndrome typically have hay fever symptoms caused by allergies to trees, grasses, and weeds. They experience irritation in the mouth (lips, tongue, roof of the mouth) and sometimes the throat after eating specific types of raw fruits, vegetables, and sometimes nuts.